1. Simultaneous Integrated Radiotherapy Boost to the Dominant Intraprostatic Lesion: Final Results of a Phase I/II Trial
- Author
-
Gabriella Macchia, Ilaria Capocaccia, Anna Rita Alitto, Giambattista Siepe, Giovanna Mantini, L. Cavallini, Edy Ippolito, Vincenzo Valentini, Savino Cilla, Milly Buwenge, Francesco Deodato, Ercole Mazzeo, Alessio G. Morganti, Buwenge M., Alitto A.R., Cilla S., Capocaccia I., Mazzeo E., Ippolito E., Mantini G., Siepe G., Cavallini L., Valentini V., Deodato F., Morganti A.G., and Macchia G.
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Intensity-modulated radiotherapy ,medicine.medical_treatment ,Urology ,Prostate neoplasm ,Disease-Free Survival ,Prostate cancer ,Prostate ,Intensity-Modulated ,80 and over ,Clinical endpoint ,Humans ,Simultaneous integrated boost ,Medicine ,Prostate neoplasms ,Dose Fractionation ,Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA ,Aged ,Aged, 80 and over ,Radiation ,Radiotherapy ,business.industry ,Genitourinary system ,Prostatic Neoplasms ,Phase I-II ,General Medicine ,Middle Aged ,Prostate-Specific Antigen ,Dominant intraprostatic lesion ,medicine.disease ,Magnetic Resonance Imaging ,Acute toxicity ,Radiation therapy ,medicine.anatomical_structure ,Image-Guided ,Oncology ,Prostatic Neoplasm ,Toxicity ,Dose Fractionation, Radiation ,Radiotherapy, Intensity-Modulated ,Neoplasm Grading ,business ,Human ,Radiotherapy, Image-Guided - Abstract
Background/aim Late toxicity and long-term outcomes of a phase I-II trial on patients with prostate cancer treated with an integrated boost to the dominant intraprostatic lesion (DIL) are reported. Patients and methods Patients were treated using intensity-modulated radiotherapy, with a simultaneous integrated boost to the DIL, defined on staging magnetic resonance imaging, delivering 72 Gy in 1.8 Gy/fraction to prostate/seminal vesicles and 80 Gy in 2 Gy/fraction to the DIL. The primary endpoint was acute toxicity and secondary endpoints were late toxicity and biochemical disease-free survival. Results Forty-four patients were enrolled. The median follow-up was 120 (range=25-150) months. Five-year rates of grade 3 late gastrointestinal and genitourinary toxicity were 2.3% and 4.5%, respectively; only one grade 4 late genitourinary toxicity was recorded. Five-year biochemical relapse-free and overall survival rates were 95.3% and 95.5%, respectively. Conclusion The treatment was well tolerated and achieved excellent results in terms of outcome in patients with low-intermediate Gleason's score and low risk of nodal metastasis.
- Published
- 2020